Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials

Journal of Clinical Microbiology

Volumn 48, Issue 12, 2010, Pages 4370-4376

  Weiner, Marc ^a   Prihoda, Thomas J ^a   Burman, William ^b   Johnson, John L ^c   Goldberg, Stefan ^d   Padayatchi, Nesri ^e   Duran, Paula ^a   Engle, Melissa ^a   Muzanye, Grace ^f   Mugerwa, Roy D ^f   Sturm, A Willem ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DENVER PUBLIC HEALTH   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; MOXIFLOXACIN;

ADULT; ARTICLE; BACTERIUM DETECTION; FEMALE; HUMAN; LUNG CAVITY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; TIME; TREATMENT FAILURE;

MYCOBACTERIUM TUBERCULOSIS;

EID: 78650038061     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00757-10     Document Type: Article

References (17)

1. Aber, V. R., and A. J. Nunn. 1978. Factors affecting relapse following short-course chemotherapy. Bull. Int. Union Tuberc. 53:260-264.
2. Benator, D., M. Bhattacharya, L. Bozeman, W. Burman, W., A. Cantazaro, R. Chaisson, F. Gordin, C. R. Horsburgh, J. Horton, A. Khan, C. Lahart, B. Metchock, C. Pachucki, L. Stanton, A. Vernon, M. E. Villarino, Y. C. Wang, M. Weiner, S. Weis, S., and the Tuberculosis Trials Consortium. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIVnegative patients: a randomised clinical trial. Lancet 360:528-534.
3. Blumberg H. M., W. J. Burman, R. E. Chaisson, R. E., C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, A. A. Vernon, American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society. 2003. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
4. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
5. Chang, K. C., C. C. Leung, W. W. Yew, S. L. Chan, and C. M. Tam. 2006. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:1153-1158.
6. Chang, K. C., C. C. Leung, W. W. Yew, S. C. Ho, and C. M. Tam. 2004. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am. J. Respir. Crit. Care Med. 170:1124-1130.
7. Conde, M. B., A. Efron, C. Loredo, G. R. M. De Souza, N. P. Graça, M. C. Cezar, M. Ramc, M. A. Chaudhary, W. R. Bishai, A. L. Kritski, and R. E. Chaisson. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
8. Dorman, S. E., J. L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C. M. Heilig, J. Bernardo, S. Choudhri, J. H. Grosset, E. Guy, P. Guyadeen, M. C. Leus, G. Maltas, D. Menzies, E. L. Nuermberger, M. Villarino, A. Vernon, R. E. Chaisson, and the Tuberculosis Trials Consortium. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
9. Epstein, M. D., N. W. Schluger, A. L. Davidow, S. Bonk, W. N. Rom, and B. Hanna. 1998. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 113:379-386.
10. Jindani, A., V. R. Baer, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
11. Joloba, M. L., J. L. Johnson, A. Namale, A. Morrissey, A. E. Assegghai, R. D. Mugerwa, J. J. Ellner, and K. D. Eisenach. 2000. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int. J. Tuber. Lung Dis. 4:528-536.
12. Mitchison, D. A. 1993. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 147:1062-1063.
13. Pheiffer, C., N. M. Carroll, N. Beyers, P. Donald, K. Duncan, and P. van Helden. 2008. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int. J. Tuber. Lung Dis. 12:792-798.
14. Rustomjee, R., A. H. Diacon, J. Allen, A. Venter, C. Reddy, R. F. Patientia, T. C. P. Mthiyane, T. De Marez, R. van Heeswijk, R. Kerstens, A. Koul, K. De Beule, P. R. Donald, and D. F. McNeeley. 2008. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:2831-2835.
15. Rustomjee, R., C. Lienhardt, T. Kanyok, G. R. Davies, J. Levin, T. Mthiyane, C. Reddy, A. W. Sturm, F. A. Sirgel, J. Allen, D. J. Coleman, B. Fourie, D. A. Mitchison, and the Gatifloxacin for TB (OFLOTUB) Study Team. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuber. Lung Dis. 12:128-138.
16. Weiner, M., J. Johnson, B. Burman, T. Prihoda, N. Padayatchi, S. Goldberg, G. Muzanye, P. Duran, W. Sturm, and the TBTC NAA Biomarker Group. 2007. Evaluation of a new surrogate endpoint for pharmacodynamics (PD) of TB drugs. Am. J. Respir. Crit. Care Med. 175:A509.
17. Weiner, M., T. Prihoda, W. Burman, J. Johnson, C. Peloquin, N. Padayatchi, M. Engle, and the Tuberculosis Trials Consortium. 2008. Pharmacodynamics of rifampin and moxifloxacin in patients with pulmonary TB. Am. J. Respir. Crit. Care Med. 177:A789.